Benitec Biopharma Stock (NASDAQ:BNTC)
Previous Close
$13.48
52W Range
$9.85 - $16.76
50D Avg
$12.20
200D Avg
$12.28
Market Cap
$423.93M
Avg Vol (3M)
$105.08K
Beta
0.26
Div Yield
$0.77
BNTC Company Profile
Benitec Biopharma Inc. is an emerging biotechnology firm dedicated to advancing groundbreaking genetic medicines. The company specializes in DNA-directed RNA interference (RNAi) based treatments, which it develops to address severe and enduring human conditions. Its pipeline features BB-301, an adeno-associated virus (AAV) gene therapy aimed at treating oculopharyngeal muscular dystrophy, and BB-103, designed to combat chronic hepatitis B virus infection. Established in 1995, Benitec Biopharma's main operations are situated in Hayward, California.